CRANBURY, N.J.--(BUSINESS WIRE)--VaxInnate announced today that it has been awarded a 2-year, $597,000 Small Business Innovation Research (SBIR) grant from the National Institutes of Health to support the development of a tetravalent Dengue virus vaccine in collaboration with scientists at the University of Texas Medical Branch at Galveston (UTMB). This SBIR grant award is the result of proof of principle studies completed in a West Nile Virus (WNV) collaboration and recently published in the Journal of Infectious Diseases.
